Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sanofi (SNW) Stock Price & Analysis

35 Followers

SNW Stock Chart & Stats

€83.72-€0.84(-0.99%)
At close: 5:30 PM GMT+1
€70€75€80€85Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
EUR 81.76 - EUR 83.77
52-Week Range
EUR 69.77 - EUR 90.75
Previous Close
EUR 84.56
Volume
N/A
Average Volume (3M)
17.08K
Market Cap
EUR 100.45B
Enterprise Value
EUR 108.09B
Total Cash (Recent Filing)
EUR 6.35B
Total Debt (Recent Filing)
EUR 23.58B
Price to Earnings (P/E)
24.6
Beta
0.58
Next Earnings
Jan 28, 2027 (Est.)
EPS Estimate
1.73
Last Dividend Ex-Date
May 05, 2026
Dividend Yield
4.92%

Bulls Say, Bears Say

Bulls Say

Cash Generation And Balance Sheet

Sanofi generates substantial operating and free cash flow with high cash conversion, while moderate leverage preserves financial flexibility. This supports research investment, business development, dividends, and resilience as the company manages portfolio changes and future exclusivity pressures.

Demand-led Revenue Growth

Strong quarterly growth supported by demand rather than one-off effects indicates broad commercial traction across Sanofi’s portfolio. The upgraded outlook reinforces near-term execution, while sustained growth can improve operating leverage and fund investment in future products.

Diversified Innovation Engine

Rapid growth from recently launched medicines and expanded access to next-generation immunology assets strengthen Sanofi’s renewal capacity. A broader launch base and external innovation platform can reduce reliance on mature products and support durable growth beyond the current portfolio.

Bears Say

Dupixent Loss-of-exclusivity Risk

Dupixent is a major growth engine, so its eventual loss of exclusivity creates a durable transition risk for revenue, earnings, and cash generation. Sanofi expects a moderate group impact, but replacing that scale requires successful launches and disciplined cost management.

Pipeline Depth And Execution Gaps

A smaller and shorter late-stage pipeline can weaken Sanofi’s ability to replenish products as competition and exclusivity pressures increase. Although R&D productivity measures are underway, development timelines and clinical outcomes make the replacement of future revenue uncertain.

Compressed Profitability

Recent declines in net margin and return on equity show that strong gross economics are not translating into prior levels of bottom-line profitability. Lower earnings conversion can constrain reinvestment and shareholder returns unless cost discipline and product mix improvements persist.

Sanofi News

SNW FAQ

What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €69.77 and its highest was €90.75 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €100.45B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s next earnings report is estimated for Jan 28, 2027 (not yet confirmed), which is in 78 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Oct 30, 2026. The company reported €3.55 earnings per share for the quarter, beating the consensus estimate of €2.788 by €0.762.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €4.12 which represents an annual dividend yield of 4.92%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.73.
How many shares outstanding does Sanofi have?
Sanofi has 1,207,773,400 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €3.55 in its last earnings report, beating expectations of €2.788. Following the earnings report the stock price went up 5.041%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in DE:SNW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology